Vaxart raises $12.5M to advance Phase I clinical trials on Avian flu vaccine (News-Medical-Net) Vaxart, Inc., a San Francisco biotechnology company developing oral-delivery vaccines, has closed a $12.5 million Series B financing, led by Care Capital of Princeton NJ. The funding will be used to advance the Company's lead product, an oral vaccine for Avian influenza, through Phase I clinical trials. [News Source]